Incyte: One molecule. Two worlds.

A tablet and a tube of cream make an odd couple. One belongs in the treatment of serious blood disorders. The other sits in a dermatologist’s world of inflamed skin and lost pigment. At Incyte, both contain ruxolitinib. The difference is where the molecule goes, how it gets there, and what the evidence allows a physician to do with it.

That pairing is a useful introduction to a company whose history contains a larger change of identity. Incyte once sold access to genomic information. Today it sells medicines. The connection between those businesses is scientific knowledge. The distance between them is the difference between understanding something and proving you can change it.

A tablet and a tube

Jakafi, Incyte’s oral ruxolitinib, received FDA approval for myelofibrosis in November 2011. Myelofibrosis scars the bone marrow, disrupts blood-cell production and can enlarge the spleen. The company’s hematology business subsequently expanded into specified patients with polycythemia vera and graft-versus-host disease, a complication of donor stem-cell transplantation.

Ruxolitinib inhibits JAK1 and JAK2, proteins involved in cellular signaling. Formulated as Opzelura cream, it reached a different specialty: dermatology. The FDA approved the cream for atopic dermatitis in 2021, then for nonsegmental vitiligo in patients aged 12 and older in July 2022. That second decision made it the first FDA-approved treatment for repigmentation in vitiligo.

The commercial logic is appealing: knowledge accumulated around one molecule can support another development program. But a cream is a separate product with separate studies and prescribing limits. Opzelura’s label carries a boxed warning concerning serious risks associated with JAK inhibitors. A familiar ingredient does not remove the obligation to establish an appropriate benefit-risk balance.

When information stopped paying

Incyte began in 1991, with Roy Whitfield and Randall Scott among its founders. Its earlier business sold genomic databases and services to pharmaceutical companies, biotechnology businesses and academic researchers. Customers paid for organized access to biological information that could help them conduct research.

The company’s 2003 annual report describes the pressure on that model with unusual clarity. Industry consolidation and a difficult economy reduced demand for research tools. Publicly available genomic information also weakened the market. In 2001, Incyte recruited Paul Friedman to lead drug discovery. In 2004, it announced the closure of its Palo Alto facility and substantial changes to its information operations.

The transition had a bill: management anticipated up to $47 million in 2004 restructuring and related charges, following $11.5 million recorded in late 2003. Those were restructuring figures, not the price of developing Jakafi. The company was exchanging one set of commercial risks for the much longer, more uncertain work of making medicines.

The control group says no

Then came a different kind of disappointment. In April 2018, Incyte and Merck reported that epacadostat added to Keytruda had failed to improve progression-free survival over Keytruda alone in advanced melanoma. The randomized study enrolled 706 patients. A plausible combination had encountered a comparison it could not beat.

The study was stopped. Incyte subsequently changed parts of the broader epacadostat program, including converting two pivotal lung-cancer trials into randomized Phase 2 studies. Here, the reason for changing course is documented: the clinical result. The experiment had answered a narrower question than the original excitement implied.

A tablet and a tube share an ingredient. They still need separate proof.

For anyone building a business, that is the copyable discipline. Reuse expertise, then test the new application on its own terms. Establish what would persuade you to stop. The lesson depends on being able to afford the experiment and act on its answer. In drug development, neither condition is cheap.

The bill behind the biology

Incyte reported approximately $2.1 billion in GAAP research and development expense for 2025. That is an annual corporate expense across programs, not a per-drug development cost. Its total revenue reached $5.14 billion. Product sales supplied most of it; royalties and milestone payments supplied the rest.

The partner network explains that mix. Novartis markets oral ruxolitinib outside the United States as Jakavi. Lilly licenses baricitinib, sold as Olumiant. Syndax and Incyte co-commercialize Niktimvo in the United States for eligible patients with chronic graft-versus-host disease after prior treatment failures. Different arrangements let Incyte earn from science without owning every commercial operation.

Its competitive position changes with the disease. In myelofibrosis, Ojjaara addresses adults with anemia; Vonjo has an indication for patients with very low platelet counts. These details matter more than a broad claim to leadership. A prescriber chooses for a particular patient, within a particular label.

The next prescription

Bill Meury became CEO in June 2025. In July 2026, Incyte completed its acquisition of Vega Therapeutics for $1.25 billion upfront, with potential sales milestones of another $750 million. The transaction added an investigational antibody for von Willebrand disease, extending the hematology portfolio into bleeding disorders. It bought a development opportunity, with clinical and regulatory work still ahead.

Incyte describes biologists and chemists working side by side, with a culture that emphasizes collaboration and employee ownership. The practical value of that arrangement is the chance to bring different scientific questions into the same conversation. Whether it produces a medicine remains a matter for experiments.

For patients and clinicians, the useful entry points are more immediate: approved-product information, support programs and sponsored-trial listings. In September 2026, Incyte and licensee Mirum announced FDA approval of zilurgisertib for eligible people with fibrodysplasia ossificans progressiva. A discovery can reach patients through a partner, too. That leaves Incyte with a recurring question: which piece of its knowledge should become the next prescription?